United Therapeutics (NASDAQ:UTHR) Sets New 12-Month High – Here’s What Happened

United Therapeutics Corporation (NASDAQ:UTHR)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $519.99 and last traded at $510.44, with a volume of 382750 shares changing hands. The stock had previously closed at $513.79.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent analyst reports. Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Finally, Oppenheimer increased their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Up 0.7%

The stock has a market cap of $22.13 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 5.11 and a beta of 0.86. The company’s fifty day moving average is $469.90 and its 200 day moving average is $385.83.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the previous year, the firm earned $6.39 earnings per share. United Therapeutics’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 50 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $512.12, for a total value of $25,606.00. Following the transaction, the director directly owned 420 shares of the company’s stock, valued at $215,090.40. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 5,950 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $512.13, for a total value of $3,047,173.50. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 595,664 shares of company stock worth $273,062,451 in the last quarter. 10.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the 2nd quarter valued at $29,000. Abich Financial Wealth Management LLC acquired a new stake in United Therapeutics during the 3rd quarter valued at $44,000. SVB Wealth LLC purchased a new stake in United Therapeutics during the 1st quarter worth $32,000. Finally, WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.